The AI in Business Podcast Rethinking Clinical Trial Operations with AI and Remote Monitoring - with Scott Bradley of Novartis
8 snips
Oct 28, 2025 Scott Bradley, Vice President of AI and Innovation at Novartis, discusses how artificial intelligence is revolutionizing clinical trials. He highlights the challenges of outdated protocols and how COVID pushed for innovation. Scott explains the evolving role of clinical staff with AI focusing on oversight. He emphasizes AI's ability to streamline protocol design and enhance patient engagement while maintaining trust through user testing. With a focus on personalized medicine, he reveals how predictive models can optimize trial processes, ultimately reshaping the future of pharmaceutical development.
AI Snips
Chapters
Transcript
Episode notes
Clinical Trials Have Built-In Inertia
- Clinical trial operations have strong institutional inertia that slows new tech adoption.
- COVID forced experimentation and broke some of that inertia, accelerating change.
Draft Protocols With Generative AI
- Use generative AI to draft protocol synopses and full study protocols from a one-page description.
- This can compress weeks of manual work into minutes for team review and iteration.
Personalization Multiplies Trial Volume
- Personalized medicine will multiply the number of smaller, targeted clinical studies.
- That increases operational complexity and creates a multiplier demand for efficient tools.